#34
Plasma Chromogranin A(CgA) and Urinary 5 Hydroxy-indoleacetic acid(5-HIAA) use in monitoring somatostatin analogue(SSA) therapy at Newcastle NHS Foundation Trust
Introduction:
Two main biochemical markers, plasma chromogranin A (CgA) and urinary 5 hydroxy-indoleacetic acid (5-HIAA) are used to aid staging and monitoring of patients with neuroendocrine (NET) tumors. Somatostatin analogues (SSA) such as octreotide and lanreotide have been used to alleviate symptoms and disease progression in NET patients. This study evaluates the use of CgA and 5HIAA in monitoring NET patients on SSA therapy at Newcastle NHS Foundation Trust.
Conference:
7th Annual ENETSConcerence (2010)
Presenting Author:
Authors:
Teo L,
Hearn K,
Bernstone G,
Wright R,
Manus D,
Keywords:
CgA,
5-HIAA,
octreotide,
lanreotide,
prognosis,
staging,
neuroendocrine tumors,
#33
Survival of Neuroendocrine Tumour Patients in Newcastle NHS Foundation Trust
Introduction:
Neuroendocrine tumors (NETs) are rare neoplasms, with an incidence of 2-2.4 per 100,000, which derive from the neurones and epithelial cells of the diffuse neuroendocrine system. Neuropeptide-secreting NETs may present with overt clinical symptoms including abdominal pain, flushing and diarrhoea, whereas non-functioning NETs may be asymptomatic or present with obstructive symptoms. In Newcastle NHS Foundation Trust, NET patients are managed with a multi-disciplinary approach, according to UK and European NET guidelines.
Conference:
7th Annual ENETSConcerence (2010)
Presenting Author:
Authors:
Hearn K,
Teo L,
Bernstone G,
Johnson S,
Perros P,
Keywords:
neuroendocrine tumor,
survival,
Ki-67 proliferation index,
metastatic disease,
